PUBLIC COMPANY
saveAvidity Biosciences Inc
updated 12d ago
community read0 votes
pipeline
3
marketed
0
phase 3
2
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 22Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Epicrispr raises $90M to rewrite treatment of rare muscle diseaseEpicrispr Biotechnologies has raised $90 million in a series C round backed by investors including Sanofi Ventures, positioning the biotech to advance a pipeline of epigenetic medicines led by an e…fiercebiotech · 22h ago
- 4 potential biotech M&A targets, plus a pretty sure bet from J&JPharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.biospace · 7d ago
- Novartis climbs on upbeat drug sales as key readouts loomA return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.biopharma_dive · 21d ago
- 10 clinical trials to watch in the second half of 2026The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.biopharma_dive · 1mo ago
- Novartis RNA drug acquired in $12B Avidity deal notches a trial winThe data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.biopharma_dive · 2mo ago
- Entrada shares dive as Duchenne results disappointWhile the company claimed a victory, analysts said data from a Phase 1/2 study fell short of expectations. Entrada shares subsequently tumbled more than 50%.biopharma_dive · 3mo ago
comments(0)
5-min edit window · permanent after that